Fenofibrate modified-release pellets with lag phase and high oral bioavailability

References

• WHOGlobal status report on noncommunicable diseases2014 Available from: http://www.who.int/nmh/publications/ncd-status-report-2014/en/Accessed October 17, 2017
   Google Scholar
• JellingerPSHandelsmanYRosenblitPDAmerican association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular diseaseEndocr Pract201723Suppl 2187
   PubMed Web of Science ®Google Scholar
• NelsonRHHyperlipidemia as a risk factor for cardiovascular diseasePrim Care201340119521123402469
   PubMed Web of Science ®Google Scholar
• RidkerPMRoseLCookNRA proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary preventionJ Am Coll Cardiol201565994294825744012
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelinesJ Am Coll Cardiol20146325 part B2889293424239923
   PubMed Web of Science ®Google Scholar
• MillerMDyslipidemia and cardiovascular risk: the importance of early preventionQJM2009102965766719498039
   PubMed Web of Science ®Google Scholar
• KohKKHow to control residual risk during the statin era?J Am Coll Cardiol20156616184826483117
   PubMed Web of Science ®Google Scholar
• JacobsonTAItoMKMakiKCNational lipid association recommendations for patient-centered management of dyslipidemia: part 1 – full reportJ Clin Lipidol20159212916925911072
   PubMed Web of Science ®Google Scholar
• TsunodaFAsztalosIBHorvathKVSteinerGSchaeferEJAsztalosBFFenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trialAtherosclerosis2016247353926854974
   PubMed Web of Science ®Google Scholar
• MKeageKKeatingGMFenofibrate: a review of its use in dyslipidaemiaDrugs201171141917194621942979
   PubMed Web of Science ®Google Scholar
• KnickelbeinJEAbbottABChewEYFenofibrate and diabetic retinopathyCurr Diab Rep201616109027525681
   PubMed Web of Science ®Google Scholar
• AthyrosVGPapageorgiouAAAthyrouVVDemitriadisDSKontopoulosAGAtorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemiaDiabetes Care20022571198120212087019
   PubMed Web of Science ®Google Scholar
• DurringtonPNTuomilehtoJHamannAKallendDSmithKRosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemiaDiabetes Res Clin Pract200464213715115063607
   PubMed Web of Science ®Google Scholar
• ReinerŽCatapanoALDe BackerGESC/EAS Guidelines for the management of dyslipidaemiasRevista Española de Cardiología2011641211681168.e6022115524
   PubMed Web of Science ®Google Scholar
• ShaoKTangYBZhouDComparison of the safety of statin monotherapy and coadministration with fenofibrate in patients with mixed hyperlipidemia: a meta-analysisInternational Journal of Clinical and Experimental Medicine2016952915300
   Web of Science ®Google Scholar
• YousafAMMustaphaOKimDWNovel electrosprayed nano-spherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrateInt J Nanomedicine20161121322126834471
   PubMed Web of Science ®Google Scholar
• ChaudharyRSAmankwaaEKumarSHuTChanMSanghviPApplication of a hot-melt granulation process to enhance fenofibrate solid dose manufacturingDrug Dev Ind Pharm20164271137114826552938
   PubMed Web of Science ®Google Scholar
• BouledjouidjaAMasmoudiYvan SpeybroeckMSchuellerLBadensEImpregnation of Fenofibrate on mesoporous silica using supercritical carbon dioxideInt J Pharm20164991–21926732521
   PubMed Web of Science ®Google Scholar
• PongsamartKKleinebuddePPuttipipatkhachornSPreparation of fenofibrate dry emulsion and dry suspension using octenyl succinic anhydride starch as emulsifying agent and solid carrierInt J Pharm20164981–234735426707411
   PubMed Web of Science ®Google Scholar
• SuhrenbrockLRadtkeGKnopKKleinebuddePPellet layering: scale-up considerations using different kinds of processing equipmentDrug Dev Ind Pharm201238121494150322452570
   PubMed Web of Science ®Google Scholar
• VogtMKunathKDressmanJBDissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparationsEur J Pharm Biopharm200868228328817574403
   PubMed Web of Science ®Google Scholar
• WengTQiJLuYThe role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulationsJ Nanobiotechnology2014123925248304
   PubMed Web of Science ®Google Scholar
• MochalinVNSagarAGourSGogotsiYManufacturing nanosized fenofibrate by salt assisted millingPharm Res20092661365137019224343
   PubMed Web of Science ®Google Scholar
• ShegokarRMüllerRHNanocrystals: industrially feasible multifunctional formulation technology for poorly soluble activesInt J Pharm20103991–212913920674732
   PubMed Web of Science ®Google Scholar
• HanafyASpahn-LangguthHVergnaultGPharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drugAdv Drug Deliv Rev200759641942617566595
   PubMed Web of Science ®Google Scholar
• LovinIAlbuFTacheFDavidVMedvedoviciASolvent and salting effects on sample preparation for the determination of fenofibric acid in human plasma by HPLC-DADMicrochemical Journal2003753179187
   Web of Science ®Google Scholar
• Van SpeybroeckMMolsRMellaertsRCombined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazoleEur J Pharm Biopharm201075335436520420905
   PubMed Web of Science ®Google Scholar
• LinZZhouDHoagSQiuYInfluence of drug properties and formulation on in vitro drug release and biowaiver regulation of oral extended release dosage formsAAPS J201618233334526769249
   PubMed Web of Science ®Google Scholar